[Shanghai RAAS: SR604 Injection Enters Phase III Clinical Trial] On September 16, Shanghai RAAS (002252.SZ) announced that the company’s product under development, “SR604 Injection,” recently announced the registration information for the Phase III clinical trial of “Preventive Treatment of Bleeding Episodes in Hemophilia A/B Patients” on the Drug Clinical Trial Registration and Information Disclosure Platform of the State Food and Drug Administration. SR604 injection is a humanized monoclonal antibody preparation that binds to human activated protein C with high affinity and specifically inhibits the anticoagulant function of human activated protein C. The company is conducting a phase III confirmatory clinical study on the indications for the prevention and treatment of bleeding episodes in patients with hemophilia A/B. It plans to conduct a multiple-dose trial of 0.4 mg/kg once every 4 weeks. If this variety is successfully developed, it is expected to significantly improve the medication experience of hemophilia A/B patients. As of the disclosure date of this announcement, there is no product with the same target as this drug on the market globally.